You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lymphoma, Extranodal NK-T-Cell

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NK/T Cell Lymphoma, Vascular Immunomother T Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Guangzhou (GNC-038)

Not yet recruiting
  • NK/T Cell Lymphoma
  • +2 more
  • Guangzhou, Guangdong, China
  • +1 more
Jan 12, 2023

Extranodal NK/T-cell Lymphoma, Nasal Type Trial (toripalimab)

Not yet recruiting
  • Extranodal NK/T-cell Lymphoma, Nasal Type
  • (no location specified)
Apr 6, 2020

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in

Completed
Has Results
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +18 more
  • Scottsdale, Arizona
  • +1 more
Sep 28, 2020

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in

Completed
Has Results
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +35 more
  • Akt inhibitor MK2206
  • laboratory biomarker analysis
  • Houston, Texas
    M D Anderson Cancer Center
Oct 14, 2020

Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With

Active, not recruiting
  • Adult Acute Lymphoblastic Leukemia in Remission
  • +46 more
  • Philadelphia, Pennsylvania
    Thomas Jefferson University
Feb 10, 2021

Extranodal Natural Killer T Cell Lymphoma Trial in China (Tislelizumab combined with Liposomal mitoxantrone HCl, Maintenance of

Recruiting
  • Extranodal Natural Killer T Cell Lymphoma
  • Tislelizumab combined with Liposomal mitoxantrone hydrochloride
  • Maintenance of tislelizumab
  • Beijing, China
  • +5 more
Jul 15, 2022

Mature T-Cell and NK-Cell Tumor Trial in Hwasun-gun (Copanlisib, Gemcitabine)

Completed
  • Mature T-Cell and NK-Cell Neoplasm
  • Hwasun-gun, Jeollanam-do, Korea, Republic of
    Chonnam National University Hwasun Hospital
Jun 9, 2022

NK/T Cell Lymphoma Nos Trial (Brentuximab Vedotin in Combination with Tislelizumab)

Not yet recruiting
  • NK/T Cell Lymphoma Nos
  • Brentuximab Vedotin in Combination with Tislelizumab
  • (no location specified)
Apr 6, 2022

Extranodal NK-T-Cell Lymphoma, Nasal Type Trial in Shanghai, Urumqi (MEDA, Auto-HSCT)

Completed
  • Extranodal NK-T-Cell Lymphoma, Nasal Type
  • Shanghai, Shanghai, China
  • +6 more
Apr 24, 2020

Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • Low-Dose Decitabine plus anti-PD-1
  • Beijing, Beijing, China
    ChinaPLAGH
Apr 18, 2023

NK Cell, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in Hubei (autologous NK cell)

Not yet recruiting
  • NK Cell
  • +2 more
  • autologous NK cell
  • Hubei, Xiangyang, China
    EC of Xiangyang No.1 People's Hospital Hubei University of Medic
Jun 19, 2023

Advanced DLBCL, Extra-nodal Involvement, Large Mass, Radiotherapy Trial (6-8 cycles (21 days per cycle) of Standard R-CHOP

Not yet recruiting
  • Advanced Diffuse Large B-Cell Lymphoma
  • +2 more
  • 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy
  • Radiotherapy beyond standard R-CHOP Chemotherapy
  • (no location specified)
May 24, 2023

Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell

Active, not recruiting
  • Recurrent Anaplastic Large Cell Lymphoma
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 30, 2023

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)

Recruiting
  • Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
  • dualCAR-NK19/70 cell
  • Shanghai, Shanghai, China
    Shanghai Tongji Hospital, Tongji University School of Medicine
Apr 24, 2023

Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Burkitt Lymphoma

Completed
Has Results
  • Adult Grade III Lymphomatoid Granulomatosis
  • +88 more
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
Apr 14, 2021

T Lymphoblastic Leukemia/Lymphoma Trial in Shenzhen (CD7 CAR-T cells)

Recruiting
  • T Lymphoblastic Leukemia/Lymphoma
  • CD7 CAR-T cells
  • Shenzhen, Guangdong, China
    Li Yu
Nov 11, 2022

B-cell Non Hodgkin Lymphoma Trial in Hanzhou (CB dualCAR-NK19/70)

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • CB dualCAR-NK19/70
  • Hanzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Dec 25, 2022

T-Cell and NK-Cell Tumor Trial

Not yet recruiting
  • T-Cell and NK-Cell Neoplasm
    • (no location specified)
    Sep 28, 2023

    NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma Trial in San Francisco, Valhalla (Methotrexate, pralatraxate,,

    Recruiting
    • NK-Cell Lymphoma
    • +2 more
    • San Francisco, California
    • +1 more
    Sep 1, 2021

    T-cell Lymphomas, NK-Cell Lymphomas Trial in United States (Ruxolitinib, Duvelisib)

    Recruiting
    • T-cell Lymphomas
    • NK-Cell Lymphomas
    • Miami, Florida
    • +8 more
    Aug 1, 2022

    Lymphoma Trial in United States (Ruxolitinib)

    Recruiting
    • Lymphoma
    • Miami, Florida
    • +9 more
    Oct 5, 2022

    Diffuse Large B Cell Lymphoma Trial (anti-CD19 CAR NK cells)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • anti-CD19 CAR NK cells
    • (no location specified)
    Dec 21, 2022

    Lymphoma Trial in Houston (Radiation Therapy, Dexamethasone, Etoposide phosphate)

    Recruiting
    • Lymphoma
    • Radiation Therapy
    • +5 more
    • Houston, Texas
      University of Texas MD Anderson Cancer Center
    Dec 9, 2022

    T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia Trial in Beijing, Shenzhen,

    Recruiting
    • T-cell Acute Lymphoblastic Leukemia
    • +3 more
    • Universal CD7-specific CAR gene-engineered T cells
    • Beijing, Beijing, China
    • +2 more
    Aug 17, 2023

    Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma Trial in

    Recruiting
    • Recurrent Anaplastic Large Cell Lymphoma
    • +9 more
    • Anti-CD30/CD16A Monoclonal Antibody AFM13
    • +4 more
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 9, 2022